Other biomarkers, such as KL-6, CXCL4, CCL2, CCL18, or surfactant protein-D (SP-D), may predict the progression of SSc-ILD but are not available in clinical practice and are currently used almost exclusively in exploratory clinical research [13,32,44]. Here, PF4 is linked to systemic sclerosis.